Last reviewed · How we verify
NCT06284746
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
Phase 2 trial testing Tirolizumab+SOX/XELOX in Locally Advanced Gastric Carcinoma in 80 participants. Status unknown.
30 April 2025
Quick facts
| Lead sponsor | Lin Chen |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 October 2023 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tirolizumab+SOX/XELOX — full drug profile →
- SOX/XELOX — full drug profile →
Conditions studied
- Locally Advanced Gastric Carcinoma — all drugs for Locally Advanced Gastric Carcinoma →
- HER2 Negative — all drugs for HER2 Negative →
- Efficacy — all drugs for Efficacy →
- Safety — all drugs for Safety →
Sponsor
Lin Chen — full company profile →
Who can join
Adults 18 to 75, any sex, with Locally Advanced Gastric Carcinoma or HER2 Negative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study objectively analyzes the safety and survival evaluation of perioperative immunotherapy combined with chemotherapy in locally advanced gastric cancer patients through a prospective randomized controlled trial research method; By comparing the pathological response rate, disease-free survival rate, and incidence of adverse events between the combination therapy and chemotherapy alone group, we aim to verify the efficacy and safety of tirelizumab combined with SOX/XELOX chemotherapy in disease control of locally advanced gastric cancer patients, laying the foundation and providing a basis for large-scale multicenter clinical research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06284746
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Gastric Carcinoma
Currently open trials in the same condition.
- NCT06364410 — Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi · Phase 1 · recruiting
- NCT05705492 — Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancre · Phase 2 · recruiting
- NCT06396143 — Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based o · recruiting
- NCT06727981 — First-Line and Neoadjuvant Immunotherapy for Gastric Cancer · recruiting
- NCT04891016 — Toripalimab Plus FLOT in Locally Advanced Gastric Cancer · Phase 2 · recruiting
Other Lin Chen trials
Trials by the same sponsor.
- NCT06493448 — Prospective Observational Cohort Study · not yet recruiting
- NCT06333379 — Aspergillosis Detection Via EBC-GM in Ventilated Patients · completed
- NCT06379568 — Risk of Aspergillus Infection in Patients With Chronic Lung Disease · completed
- NCT06390748 — Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes · Phase 2 · completed
- NCT05334849 — Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06284746 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lin Chen
- Last refreshed: 29 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06284746.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing